Orphan Drug Development Pricing And Access

Dennis Jackman of CSL Behring had a 'fireside chat' with Peter Saltonstall of the National Organization of Rare Disorders ...

Last week, we argued that the benefits of the

We have a short video featuring Beate Løkke, our Director of Market

Robert Derham, Founder of CheckOrphan discusses the

Day 1: General Session, Value,

In the United States, the median

In this series '

According to Dr. Kakkis, most believe that the

Within the European Joint Programme for Rare diseases, EATRIS and the EMA's Regulatory Science and Innovation Task Force ...

Minimising uncertainty for biopharmaceutical payers and manufacturers is a key factor in maximising

Welcoming Remarks and Panel 1 (Contextual Considerations and Ethical Issues)

Drug companies love the

Skyrocketing

In this series '

Orphan Drug

Joshua P. Cohen, PhD, Tufts Center for the Study of Drug

Barry Greene, President and COO of Alnylam Pharmaceuticals explains why Boston and Cambridge are where most

Have you ever wondered how

Mtech

Reference Reference Divino V, Dekoven M, Wang W, et al. Budget impact of